7.5.3 TRANSLATIONAL METHODOLOGIES DEVELOPMENT PROJECT A large number of molecular abnormalities contribute to the cancer phenotype. Investigators have demonstrated that inhibition of these targets by some compounds affects cancer phenotypes in model systems. What is frequently missing from these efforts is a method to turn an observation, or even a compound, into a drug that can be tested in human clinical trials. This problem is not restricted to cancer therapies, and this has been recognized by the University's AHC. A substantial commitment to the development of new therapies, as outlined above by Dr. Cerra's conceptual framework of "Research Corridors'* has led to the development of two separate new efforts, the Institute of Therapeutic Discovery and Development (ITDD) and the Center for Translational Medicine (CTM). For these developmental funds, we request support for a new technology/methodology resource, termed Translational Methodologies. The purpose is to facilitate translation of basic laboratory studies into the clinic by engaging the ITDD and the CTM in a joint, integrated effort to bring new small molecule inhibitors, drugs, proteins or cells into phase I clinical cancer trials. Funds will be used to provide staff for translational methodologies that will develop specific high priority projects toward phase I trials,

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-15
Application #
8449975
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$99,686
Indirect Cost
$33,669
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Abbott, Kenneth L; Nyre, Erik T; Abrahante, Juan et al. (2015) The Candidate Cancer Gene Database: a database of cancer driver genes from forward genetic screens in mice. Nucleic Acids Res 43:D844-8
Yee, Douglas (2015) A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clin Cancer Res 21:667-9
Daniel, A R; Gaviglio, A L; Knutson, T P et al. (2015) Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene 34:506-15
Upadhyaya, Pramod; Hecht, Stephen S (2015) Quantitative analysis of 3'-hydroxynorcotinine in human urine. Nicotine Tob Res 17:524-9
Patel, Yesha M; Stram, Daniel O; Wilkens, Lynne R et al. (2015) The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. Cancer Epidemiol Biomarkers Prev 24:119-27
Takahashi, Yutaka; Hui, Susanta K (2014) Fast, simple, and informative patient-specific dose verification method for intensity modulated total marrow irradiation with helical tomotherapy. Radiat Oncol 9:34
Cooley, Sarah; Weisdorf, Daniel J; Guethlein, Lisbeth A et al. (2014) Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192:4592-600
Chen, Liddy M; Ibrahim, Joseph G; Chu, Haitao (2014) Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses. J Biopharm Stat 24:817-33
Landman, Sean R; Hwang, Tae Hyun; Silverstein, Kevin A T et al. (2014) SHEAR: sample heterogeneity estimation and assembly by reference. BMC Genomics 15:84
Gates, Leah A; Phillips, Martin B; Matter, Brock A et al. (2014) Comparative metabolism of furan in rodent and human cryopreserved hepatocytes. Drug Metab Dispos 42:1132-6

Showing the most recent 10 out of 319 publications